Built on the authoritative federal record
The primary sources, named on every page.
These are the federal agencies whose public datasets Fonteum ingests and attributes — the issuing authorities, not customers or partners. Every figure on the site links back to one of them.
See the full source registry, with license and refresh cadence for each →
Reproducible by design
Every figure traces to its federal source.
14-tuple provenance
Every rendered fact ties to a source URL, dataset ID, snapshot date, row key, and SHA-256 — the full chain-of-custody record.
Reproducible SQL
Each study ships the exact query behind its figures, run against the cited federal snapshot. Re-run it yourself.
Daily reconciliation
Published counts are reconciled against the upstream federal datasets on a daily cadence, with drift logged.
Named medical review
Reviewed by Jennifer Montecillo, MD, medical reviewer. Non-practicing medical reviewer.
Two doors
Use the free API and open data
Query providers, facilities, sanctions, and quality scores — each field carrying its federal source. Self-serve, no call to start.
Talk to us
Managed pilots, enterprise terms, and audit-ready, signed attestation packages for compliance, risk, and research teams.
The substrate, by the numbers
Cross-source identity
National Provider Identifier 1003015173 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|---|---|---|
| CMS NPPES |
| NPI 1003015173 |
| Registry identity — dermatologist, taxonomy 207N00000X |
| Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Medicare Part D | NPI 1003015173 | 40 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity 64c8c94d… | Canonical resolved node · 3 identifier(s) · 0 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Skyrizi Pen(Risankizumab-Rzaa) | 25 | $470,657 |
| Humira(Cf) Pen(Adalimumab) | 28 | $309,254 |
| Cosentyx Unoready Pen(Secukinumab) | 24 | $197,686 |
| Stelara(Ustekinumab) | 11 | $187,304 |
| Otezla(Apremilast) | 16 | $71,776 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
Record history
Every field on this record is stored bitemporally — both when the fact was true in the world and when Fonteum recorded it. Open the time-travel view to reconstruct this record as of any past date, or to read each field with the source and dates behind it.